Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation

Annals of Thoracic Surgery

Volumn 62, Issue 5, 1996, Pages 1467-1473

  Reichenspurner, Hermann ^a   Girgis, Reda E ^a   Robbins, Robert C ^a   Yun, Kwok L ^a   Nitschke, Michael ^a   Berry, Gerald J ^a   Morris, Randall E ^a   Theodore, James ^a   Reitz, Bruce A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRONCHIOLITIS; CONTROLLED STUDY; FOLLOW UP; HEART LUNG TRANSPLANTATION; HUMAN; LUNG FUNCTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030297035     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00776-X     Document Type: Article

References (22)

1. 1. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984;86:824-9.
2. 2. Griffith BP, Hardesty RL, Armitage JM, et al. A decade of lung transplantation. Ann Surg 1993;218:310-20.
3. 3. Wallwork J. Risk factors for chronic rejection in heart and lungs - why do hearts and lungs rot? Clin Transplant 1994;8: 341-4.
4. 4. Reichenspurner H, Girgis R, Robbins RC, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 1995;60:1845-53.
5. 5. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110: 4-13.
6. 6. Sundaresan S, Trulock EP, Cooper JD, Patterson AG. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group. Ann Thorac Surg 1995;60:1341-6.
7. 7. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993;12:713-6.
8. 8. Yousem SA, Sartori D, Sonmez-Alpan E. Multidrug resistance in lung allograft recipients: possible correlation with the development of acute and chronic rejection. J Heart Lung Transplant 1993;12:20-6.
9. 9. Kramer MR, Stoehr C, Whang JL, et al. The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy. J Heart Lung Transplant 1993;12:675-81.
10. 10. Reichenspurner H, Gamberg P, Yun K. Aerolized amphotericin B prophylaxis significantly reduces the number of fungal infections after heart-lung and lung transplantation. J Heart Lung Transplant 1996;15(Suppl):56.
11. 11. Hertz MI, Jessurun J, King MB, et al. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol 1993;142:1945-51.
12. 12. Huang XH, Reichenspurner H, Shorthouse R, et al. Heterotopic tracheal allograft transplantation: a new model to study the molecular events causing obliterative airway disease (OAD) in rats [Abstract]. J Heart Lung Transplant 1995; 14(Suppl):49.
13. 13. Maurer JR. Lung transplantation bronchiolitis obliterans. In: Epler GR, ed. Diseases of the bronchioles. New York: Raven Press, 1994:275-89.
14. 14. Girgis RE, Tu I, Berry GB. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996;15(Suppl):65.
15. 15. Reichenspurner H, Soni V, Brazelton T. Enhancement of obliterative airway disease in rat tracheal allografts infected with genetically engineered cytomegalovirus. J Heart Lung Transplant 1996;15(Suppl):45.
16. 1). J Heart Lung Transplant (in press).
17. 17. Bassiri AG, Girgis R, Theodore J. Utility of specific airway conductance in the diagnosis of obliterative bronchiolitis after lung transplantation. Presented at the 16th Annual Meeting and Scientific Sessions of the Society for Heart and Lung Transplantation, New York, NY, March 15-18, 1996.
18. 18. Yousem SA, Paradis I, Griffith BP. Can transbronchial biopsy aid in the diagnosis of bronchiolitis obliterans in lung transplant recipients? Transplantation 1994;57:151-3.
19. 19. Morris R, Huang XH, Shorthouse R, et al. Use of cyclosporine (CsA), mycophenolic acid (MPA), rapamycin (RPM), leflunomide (LFM), or desoxyspergualin (DSG) for prevention and treatment of obliterative airway disease in rats. J Heart Lung Transplant 1995;14(Suppl):65.
20. 20. Reichenspurner H, Huang X, Soni V, et al. Pathogenesis and treatment of obliterative airway disease after heterotopic tracheal allograft and xenograft transplantation. Surg Forum 1995;46:456-8.
21. 21. Cao W, Mohacsi P, Shorthouse R, et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995;59:390-5.
22. 22. Nair R, Cao W, Morris RE. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol Lett 1995;47: 171-174.